ZA200604971B - 3-Cyano-quinoline derivatives with antiproliferative activity - Google Patents

3-Cyano-quinoline derivatives with antiproliferative activity

Info

Publication number
ZA200604971B
ZA200604971B ZA200604971A ZA200604971A ZA200604971B ZA 200604971 B ZA200604971 B ZA 200604971B ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 A ZA200604971 A ZA 200604971A ZA 200604971 B ZA200604971 B ZA 200604971B
Authority
ZA
South Africa
Prior art keywords
cyano
antiproliferative activity
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
ZA200604971A
Other languages
English (en)
Inventor
Freyne Eddy Jean Edgard
Van Emelen Kristof
Timothy Pietro Suren Perera
Peter Jacobus Johannes Antonius Buijnsters
Werner Constan Johan Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200604971(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200604971B publication Critical patent/ZA200604971B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200604971A 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity ZA200604971B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EPPCT/EP03/51059 2003-12-18

Publications (1)

Publication Number Publication Date
ZA200604971B true ZA200604971B (en) 2009-05-27

Family

ID=34684508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604971A ZA200604971B (en) 2003-12-18 2006-06-15 3-Cyano-quinoline derivatives with antiproliferative activity

Country Status (23)

Country Link
US (4) US7655642B2 (ja)
EP (1) EP1696914B1 (ja)
JP (1) JP4892353B2 (ja)
KR (1) KR101158440B1 (ja)
CN (1) CN1893944B (ja)
AR (1) AR047060A1 (ja)
AT (1) ATE446750T1 (ja)
AU (1) AU2004298784B2 (ja)
BR (1) BRPI0417609B8 (ja)
CA (1) CA2549728C (ja)
DE (1) DE602004023876D1 (ja)
EA (1) EA200601176A1 (ja)
ES (1) ES2335216T3 (ja)
HK (1) HK1095742A1 (ja)
IL (1) IL176358A (ja)
MX (1) MXPA06007018A (ja)
NO (1) NO337622B1 (ja)
NZ (1) NZ547795A (ja)
SG (1) SG151288A1 (ja)
TW (2) TWI374879B (ja)
UA (1) UA83880C2 (ja)
WO (1) WO2005058318A1 (ja)
ZA (1) ZA200604971B (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
CN1893944B (zh) 2003-12-18 2011-07-06 詹森药业有限公司 具有抗增殖活性的3-氰基喹啉衍生物
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
ATE469158T1 (de) * 2005-11-16 2010-06-15 S Heteroalkylgebundene pyrimidinderivate
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
JP2009542778A (ja) * 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Mtkiキナゾリン誘導体
EP2123627B1 (en) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group
DK2170827T3 (da) * 2007-06-21 2013-11-18 Janssen Pharmaceutica Nv Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028613A (en) 1990-02-16 1991-07-02 Repligen Corporation Novel pyrroloquinoline alkaloids and methods of use
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
JP4548642B2 (ja) * 1998-09-29 2010-09-22 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換3−シアノキノリン
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
KR101064530B1 (ko) * 2002-03-30 2011-09-14 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티로신 키나아제 억제제로서의 4-(n-페닐아미노)-퀴나졸린/퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
CN1893944B (zh) * 2003-12-18 2011-07-06 詹森药业有限公司 具有抗增殖活性的3-氰基喹啉衍生物

Also Published As

Publication number Publication date
US9040511B2 (en) 2015-05-26
US9365517B2 (en) 2016-06-14
BRPI0417609B1 (pt) 2019-02-19
BRPI0417609B8 (pt) 2021-05-25
MXPA06007018A (es) 2006-08-31
EP1696914A1 (en) 2006-09-06
NO20063324L (no) 2006-07-18
SG151288A1 (en) 2009-04-30
JP2007514711A (ja) 2007-06-07
NZ547795A (en) 2009-07-31
ES2335216T3 (es) 2010-03-23
AR047060A1 (es) 2006-01-04
HK1095742A1 (en) 2007-05-18
EP1696914B1 (en) 2009-10-28
IL176358A0 (en) 2006-10-05
IL176358A (en) 2010-06-16
KR101158440B1 (ko) 2012-07-06
BRPI0417609A (pt) 2007-04-10
CN1893944B (zh) 2011-07-06
UA83880C2 (en) 2008-08-26
TWI389890B (zh) 2013-03-21
CN1893944A (zh) 2007-01-10
US20080139601A1 (en) 2008-06-12
US20140256948A1 (en) 2014-09-11
CA2549728C (en) 2015-07-21
US20100069424A1 (en) 2010-03-18
AU2004298784B2 (en) 2011-06-09
US20130197022A1 (en) 2013-08-01
ATE446750T1 (de) 2009-11-15
NO337622B1 (no) 2016-05-09
KR20070005560A (ko) 2007-01-10
CA2549728A1 (en) 2005-06-30
AU2004298784A1 (en) 2005-06-30
JP4892353B2 (ja) 2012-03-07
TW200530187A (en) 2005-09-16
EA200601176A1 (ru) 2006-10-27
WO2005058318A1 (en) 2005-06-30
US8778920B2 (en) 2014-07-15
TWI374879B (en) 2012-10-21
US7655642B2 (en) 2010-02-02
TW201132628A (en) 2011-10-01
DE602004023876D1 (de) 2009-12-10

Similar Documents

Publication Publication Date Title
IL176358A0 (en) 3-cyano-quinoline derivatives with antiproliferative activity
SI1583763T1 (sl) Benzoazolilpiperazinski derivati, ki imajo VR1 antagonistično delovanje
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
SI1551802T1 (sl) Indol žveplovi derivati
EP1522540A4 (en) AZAARENE DERIVATIVES
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
PL375588A1 (en) Pyrimido compounds having antiproliferative activity
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
HK1129681A1 (en) Macrolide-conjugates with anti-inflammatory activity
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
DE60326941D1 (en) Rs
HK1099649A1 (en) Pesticidal 5-substituted-oxyalkylamino-1-arylpyrazole derivatives 5--
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
MY144310A (en) 3-cyano-quinoline deriatives with antiproliferative activity
AU2003243397A8 (en) Homo-camptothecin derivatives